Ceribell (CBLL) Preferred Stock Liabilities (2023 - 2024)
Ceribell's (CBLL) quarterly Preferred Stock Liabilities came in at $988000.0 in Q3 2024, down 99.33% YoY from $147.4 million in Q4 2023, and down 99.33% on a QoQ basis from $147.4 million in Q2 2024.
Ceribell (CBLL) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Ceribell (CBLL) has 2 years of Preferred Stock Liabilities data on file, last reported at $988000.0 in Q3 2024.
- Quarterly Preferred Stock Liabilities fell 99.33% year-over-year to $988000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $988000.0 (down 99.33% YoY) and the FY2023 annual result came in at $35.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $988000.0 in Q3 2024, from $147.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $147.4 million in Q3 2023 to a low of $988000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | Ceribell | 923.42 Mn | 794.16 Mn | 25.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 988,000.00 |
| Jun 30, 2024 | 147.41 Mn |
| Mar 31, 2024 | 147.41 Mn |
| Dec 31, 2023 | 35.40 Mn |
| Sep 30, 2023 | 147.41 Mn |